| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. | Chief Medical Officer | Common Stock | 150,358 | 29 Jan 2026 | Direct | ||
| Apogee Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 14,461 | 17 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PLYX | Polaryx Therapeutics, Inc. | 29 Jan 2026 | 0 | $0 | 3 | Chief Medical Officer | 29 Jan 2026, 16:43 |
| APGE | Apogee Therapeutics, Inc. | 17 Jun 2025 | 1 | $0 | 4 | Director | 20 Jun 2025, 20:00 |
| APGE | Apogee Therapeutics, Inc. | 05 Jun 2024 | 1 | $0 | 4 | Director | 07 Jun 2024, 20:04 |
| APGE | Apogee Therapeutics, Inc. | 28 May 2024 | 1 | $0 | 4 | Director | 30 May 2024, 20:07 |
| APGE | Apogee Therapeutics, Inc. | 28 May 2024 | 0 | $0 | 3 | Director | 30 May 2024, 20:05 |